南昌大学学报(医学版)
南昌大學學報(醫學版)
남창대학학보(의학판)
Acta Academiae Medicinae Jiangxi
2015年
5期
1-4,107
,共5页
刘涛%候雄军%伍锡栋%柯波%王蓉%刘素珍
劉濤%候雄軍%伍錫棟%柯波%王蓉%劉素珍
류도%후웅군%오석동%가파%왕용%류소진
叶酸%分子靶向%顺铂%纳米药物%鼻咽癌%动物,实验%裸鼠
葉痠%分子靶嚮%順鉑%納米藥物%鼻嚥癌%動物,實驗%裸鼠
협산%분자파향%순박%납미약물%비인암%동물,실험%라서
folic acid%molecular targeted%nanomedicine%nasopharyngeal carcinoma%cisplatin
目的:探讨叶酸(folic acid,FA)分子靶向载顺铂(cisplatin,CDDP)羧甲基-β-环糊精(carboxymethyl-β-cyclo-dextrin,CM-β-CD)纳米药物(FA-CM-β-CD-CDDP)对鼻咽癌(nasopharyngeal carcinoma,NPC)的体内靶向治疗效应。方法荷叶酸受体(folate receptor,FR)表达阳性的 HNE-1瘤和 FR 表达阴性的 CNE-2瘤的同一裸鼠经尾静脉给予 FA-CM-β-CD-CDDP 纳米药物(按 CDDP 10 mg·kg-1给药)1.5 h 后,采用原子吸收光谱法检测2种瘤块组织内的 CDDP 浓度,分析 FA-CM-β-CD-CDDP 的体内靶向能力。将20只荷 HNE-1瘤裸鼠按随机数字表法分为4组(每组5只),均经尾静脉注射给药0.2 mL:对照组注射生理盐水,载体组注射 FA-CM-β-CD 溶液,CDDP 组注射浓度为3 mg·kg-1的 CDDP 溶液,纳米药物组注射 FA-CM-β-CD-CDDP 溶液(含 CDDP 浓度3 mg·kg-1),给药后21 d 测量各组 HNE-1瘤块体积和质量,并采用免疫组化检测瘤块增殖细胞核抗原(proliferating cell nuclear anti-gen,PCNA)表达,分析 FA-CM-β-CD-CDDP 的体内肿瘤抑制效应。结果 HNE-1肿瘤组织内 CDDP 含量明显高于 CNE-2肿瘤组织(P <0.05)。纳米药物组的 HNE-1瘤块体积和质量抑瘤率分别为43.36%、41.67%,较载体组(7.91%、5.56%)和 CDDP 组(24.51%、22.22%)均明显增加;且 HNE-1瘤块 PCNA 阳性细胞指数为47.75%,表达较对照组(90.83%)、载体组(89.62%)和 CDDP 组(68.43%)均明显降低。结论构建的 FA-CM-β-CD-CDDP纳米药物能够靶向抑制 FR 阳性的 NPC 瘤块生长。
目的:探討葉痠(folic acid,FA)分子靶嚮載順鉑(cisplatin,CDDP)羧甲基-β-環糊精(carboxymethyl-β-cyclo-dextrin,CM-β-CD)納米藥物(FA-CM-β-CD-CDDP)對鼻嚥癌(nasopharyngeal carcinoma,NPC)的體內靶嚮治療效應。方法荷葉痠受體(folate receptor,FR)錶達暘性的 HNE-1瘤和 FR 錶達陰性的 CNE-2瘤的同一裸鼠經尾靜脈給予 FA-CM-β-CD-CDDP 納米藥物(按 CDDP 10 mg·kg-1給藥)1.5 h 後,採用原子吸收光譜法檢測2種瘤塊組織內的 CDDP 濃度,分析 FA-CM-β-CD-CDDP 的體內靶嚮能力。將20隻荷 HNE-1瘤裸鼠按隨機數字錶法分為4組(每組5隻),均經尾靜脈註射給藥0.2 mL:對照組註射生理鹽水,載體組註射 FA-CM-β-CD 溶液,CDDP 組註射濃度為3 mg·kg-1的 CDDP 溶液,納米藥物組註射 FA-CM-β-CD-CDDP 溶液(含 CDDP 濃度3 mg·kg-1),給藥後21 d 測量各組 HNE-1瘤塊體積和質量,併採用免疫組化檢測瘤塊增殖細胞覈抗原(proliferating cell nuclear anti-gen,PCNA)錶達,分析 FA-CM-β-CD-CDDP 的體內腫瘤抑製效應。結果 HNE-1腫瘤組織內 CDDP 含量明顯高于 CNE-2腫瘤組織(P <0.05)。納米藥物組的 HNE-1瘤塊體積和質量抑瘤率分彆為43.36%、41.67%,較載體組(7.91%、5.56%)和 CDDP 組(24.51%、22.22%)均明顯增加;且 HNE-1瘤塊 PCNA 暘性細胞指數為47.75%,錶達較對照組(90.83%)、載體組(89.62%)和 CDDP 組(68.43%)均明顯降低。結論構建的 FA-CM-β-CD-CDDP納米藥物能夠靶嚮抑製 FR 暘性的 NPC 瘤塊生長。
목적:탐토협산(folic acid,FA)분자파향재순박(cisplatin,CDDP)최갑기-β-배호정(carboxymethyl-β-cyclo-dextrin,CM-β-CD)납미약물(FA-CM-β-CD-CDDP)대비인암(nasopharyngeal carcinoma,NPC)적체내파향치료효응。방법하협산수체(folate receptor,FR)표체양성적 HNE-1류화 FR 표체음성적 CNE-2류적동일라서경미정맥급여 FA-CM-β-CD-CDDP 납미약물(안 CDDP 10 mg·kg-1급약)1.5 h 후,채용원자흡수광보법검측2충류괴조직내적 CDDP 농도,분석 FA-CM-β-CD-CDDP 적체내파향능력。장20지하 HNE-1류라서안수궤수자표법분위4조(매조5지),균경미정맥주사급약0.2 mL:대조조주사생리염수,재체조주사 FA-CM-β-CD 용액,CDDP 조주사농도위3 mg·kg-1적 CDDP 용액,납미약물조주사 FA-CM-β-CD-CDDP 용액(함 CDDP 농도3 mg·kg-1),급약후21 d 측량각조 HNE-1류괴체적화질량,병채용면역조화검측류괴증식세포핵항원(proliferating cell nuclear anti-gen,PCNA)표체,분석 FA-CM-β-CD-CDDP 적체내종류억제효응。결과 HNE-1종류조직내 CDDP 함량명현고우 CNE-2종류조직(P <0.05)。납미약물조적 HNE-1류괴체적화질량억류솔분별위43.36%、41.67%,교재체조(7.91%、5.56%)화 CDDP 조(24.51%、22.22%)균명현증가;차 HNE-1류괴 PCNA 양성세포지수위47.75%,표체교대조조(90.83%)、재체조(89.62%)화 CDDP 조(68.43%)균명현강저。결론구건적 FA-CM-β-CD-CDDP납미약물능구파향억제 FR 양성적 NPC 류괴생장。
ABSTRACT:Objective To investigate the effect of folic acid(FA)-targeted cisplatin(CDDP)con-jugated carboxymethyl-β-cyclodextrin(CM-β-CD)nanomedicine(FA-CM-β-CD-CDDP)on naso-pharyngeal carcinoma(NPC)in vivo.Methods Nude mice bearing folate receptor(FR)-positive HNE-1 tumor and FR-negative CNE-2 tumor were given FA-CM-β-CD-CDDP nanomedicine(CD-DP 10 mg·kg-1 )via tail vein injection.The concentrations of CDDP in tumor tissues were deter-mined 1.5 hours after injection by using atomic absorption spectroscopy to analyze the targeting ability of FA-CM-β-CD-CDDP.Twenty nude mice bearing HNE-1 tumor were randomly given normal saline(control group,n=5),FA-CM-β-CD solution(vector group,n=5),3 mg·kg-1 CD-DP solution(CDDP group,n=5)or 3 mg/kg FA-CM-β-CD-CDDP solution(nanomedicine group, n=5)at a volume of 2 ml via tail vein injection.HNE-1 tumor volume and weight were measured 21 days after administration.Furthermore,the expression of proliferating cell nuclear antigen(PC-NA)was detected by immunohistochemistry to analyze the efficacy of FA-CM-β-CD-CDDP for tumor suppression.Results The concentration of CDDP in HNE-1 tumor was significantly higher than that in CNE-2 tumor(P <0.05).The inhibition rates of HNE-1 tumor volume and weight in nanomedicine group(43.36% and 41.67%,respectively)were significantly higher than those in vector group(7.91% and 5.56%,respectively)and CDDP group(24.51% and 22.22%,respec-tively).Moreover,positive PCNA index in HNE-1 tumor in nanomedicine group(47.75%)was significantly lower than that in control group(90.83%),vector group(89.62%)and CDDP group (68.43%).Conclusion The constructed A-CM-β-CD-CDDP nanomedicine can inhibit the growth of FR-positive NPC tumor.